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Abstract: Reference intervals for common hematological and clinical chemistry 
parameters constitute an important basis for health care. Moreover, with increasing priority 
in drug and vaccine development for infectious diseases in Africa, the first priority is the 
safety evaluation and tolerability of the candidate interventions in healthy populations.  
To accurately assess health status and address adverse events, clinical reference intervals in 
the target population are necessary. We report on hematological and biochemical indices 
from healthy volunteers who participated in a clinical trial in Lira, northern Uganda. 
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Median and nonparametric 95% percentiles on five hematology and 15 biochemistry 
analytes are shown. Although most hematological analytes conformed to reported 
reference intervals and trends in Africa, literature review from different African countries 
highlight the need for a region-specific children reference interval that can be appropriate 
for the population. 
Keywords: reference intervals; clinical trials; hematology; biochemistry; adult reference 
values; children reference values 
 
1. Introduction 
Reference intervals are used to describe the dispersion or fluctuation of analytes in healthy 
individuals; as indicators of good health or for accurate interpretation of physiological or pathological 
conditions in clinical and research environments. They are of particular importance in clinical trials 
especially in Africa [1], guiding the screening and enrollment of prospective participants as well as the 
safety assessment of investigational products. Phase I/II trials rely on enrollment and assessment of 
healthy participants for proper safety evaluation of interventions prior to phase III trials where safety 
and efficacy are evaluated on a larger scale. In April–May and September–October 2010, screening for 
enrollment in a phase Ib age de-escalation vaccine trial to assess the safety and immunogenicity of the 
BK-SE36 malaria vaccine was conducted at Lira Medical Centre (LMC), Lira, Uganda [2]. The trial 
assessed for eligibility 100 adults (>21 year-old) and 150 volunteers aged 6–20 years. Inclusion and 
exclusion criteria were based on reference values obtained from LMC as well as from a number of 
publications that address reference intervals in Africa [3–7]. From our experience, the reference values 
were not easily applicable to the phase 1b clinical trial, one of the reasons that contributed to a high 
screening to enrollment ratio. This resulted in logistical, personnel, as well as financial concerns. 
Reference intervals could also falsely exclude otherwise eligible volunteers making the process of trial 
recruitment and enrollment challenging. Likewise, inappropriate participant selection may bias trial 
results such that data become less generalizable to the healthy population being studied. 
Prior to 2008, in most large-population based reference interval studies, the health status of 
participants were not assessed thoroughly and no additional medical or laboratory examinations were 
performed [3,4]. Majority of the reports also focused only on adults [3,4,8–10] and few included 
biochemistry reference values [5–7,11]. With publication of the International Federation of Clinical 
Chemistry (IFCC) and Clinical and Laboratory Standards Institute (CLSI) revised guidelines in  
2008 [12], reference interval studies in Africa have increased [13–17] with some including children in 
their analyses [18,19]. These studies demonstrate differences in reference values compared to 
established US reference intervals [5,7,13,14,16,19,20]. 
Here, we present hematological and biochemical indices of healthy volunteers aged 6–32 years old 
who participated in the Phase Ib clinical trial. From the screening of healthy volunteers, we had the 
opportunity to collect and compare both hematological and biochemical data from these volunteers and 
re-assess previously reported reference intervals in Uganda as well as in Africa. Besides, the  
well-defined inclusion and exclusion criteria applied in the trial represent a data set from a northern 
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Uganda population that can typically participate in intervention trials and vaccine studies. The results 
also underscore the need for region-specific children reference intervals that can be more appropriate 
for the population.  
2. Experimental Section  
2.1. Study Population 
In this study, only the screening visit data of volunteers who participated in the BK-SE36 Phase Ib 
clinical trial [2] was included in the analysis. The study took place at Lira Medical Center in Lira 
district, Northern Uganda. Lira district is approximately 1063 m above sea level and lies 347 km north 
of Kampala, the capital of Uganda. The district is predominantly agricultural, with the population 
comprising largely small landholder subsistence farmers: growing beans and cassava; owning chicken 
and goats [21]. The staple foods are mainly maize, cassava, sorghum and sweet potatoes. The area has 
a tropical climate with a temperature range of 17.4–30.3 °C and an average rainfall of 1478 mm/year [21].  
Briefly, there were two stages of screening. Stage 1 was in 21–40 year-olds (n = 56) and Stage 2 
was in 3 age cohorts (6–10, 11–15 and 16–20 years old). Screening for Stage 1 was conducted in 
April–May 2010 and for Stage 2 in September–October 2010. The trial was conducted in compliance 
with the study protocol, the International Conference on Harmonization’s Good Clinical Practice 
standards, the Declaration of Helsinki and Uganda regulatory requirements. Approvals for the protocol, 
subject information and informed consent forms were obtained from the ethical institutional review 
committees (IRC) of Osaka University (RIMD-IRC) (Japan), Research Foundation for Microbial 
Diseases of Osaka University (BIKEN-IRC) (Japan), Med Biotech Laboratories (MBL-IRC) (Uganda), 
and regulatory bodies Uganda National Council for Science and Technology (UNCST) and the Uganda 
National Drug Authority (NDA). Informed consent was obtained in English, Swahili or Luo (the 
language commonly spoken locally). Written consent was obtained from all enrolled subjects, in 
addition to individual assent from children aged eight and above. All participants were screened 
through a medical history questionnaire and complete physical examination. Females of child bearing 
age were tested for pregnancy. Selected participants were healthy, with no obvious symptoms/signs of 
either acute or chronic respiratory, cardiovascular, gastrointestinal, hepatic or renal disease; no history 
of blood donation/transfusion within one month and, for females, non-lactating. A detailed report of 
the study population recruitment, enrollment, inclusion/exclusion criteria, and blood sampling has been 
published [2]. 
Whole blood samples were collected from fasting subjects via venipuncture with a Vacutainer 
system (Becton Dickinson Biosciences, Franklin Lakes, NJ, USA), with all blood drawn in the 
morning (7:00–12:00 am) and hematological and biochemistry tests performed within the day. The 
samples were also checked for malaria parasites. Blood sampling and processing were done according 
to standard operating procedures by trained laboratory staff (EDTA treated tubes for hematology and 
untreated tubes for biochemistry tests). Hematological indices were measured by Sysmex KX-21N 
(Sysmex Corporation, Kobe, Japan); and biochemical indices by Cobas C111 (Roche Diagnostics, 
Mannheim, Germany) per manufacturer’s instructions. Daily quality control was performed on the 
equipment and all laboratory procedures adhered to Good Clinical Laboratory Practices. Calibrators 
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and controls were obtained from the instrument manufacturer. For hematology tests, daily running of 
the 3-part Differential Whole Blood Para® Check (Para® Check Low, Para® Check Normal and Para® 
Check High) controls ensured calibration and quality control limits for each analyte. For Cobas C111, 
we used normal (PreciNorm U) and abnormal (PreciPath U) control sera from Roche Diagnostics.  
In addition, the laboratory was under an external quality assurance program with the South African 
National Accreditation System. Assessments included white blood cell (WBC) count, red blood cell 
(RBC) count, hemoglobin (Hb), hematocrit (Hct), platelet count, alkaline phosphatase (AL-P), alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), γ-glutamyl-transferase (-GTP), amylase, 
albumin, total protein, total bilirubin, cholesterol, glucose, creatinine, urea nitrogen (BUN), uric acid, 
potassium and sodium. 
2.2. Statistical Methods 
Data were pooled, analyzed untransformed and are shown as mean, median, maximum-minimum 
values, and 95% reference intervals according to CLSI C28-A3 guideline [12]. Of the measured 
analyte, 70% did not conform to a Gaussian distribution according to the D’Agostino and Pearson and 
Shapiro-Wilk tests for normality. Outlier exclusion was the recommended Dixon-Reed’s outlier 
method. Non-parametric percentiles and 90% CIs were determined. Possible partitioning to two broad 
age groups: 6–15 years-old and 16–32 years-old were done using the robust method with possible 
outliers detected by visual inspection of distributions and Tukey’s criterion. Analytes that have 
significant age differences based on the non-parametric Mann-Whitney U test are shown in Table 3. 
Statistical analyses were performed using MedCalc for Windows, version 13.1.1.0 (MedCalc Software, 
Ostend, Belgium) and GraphPad Prism 6 (GraphPad Software; La Jolla, CA, USA).  
3. Results and Discussion 
3.1. Baseline Characteristics of the Study Population 
From April–May and September–October 2010 (two sampling periods), we enrolled a total of 140 
healthy individuals [2]. We report on the health status of these individuals based on hematological and 
biochemical data obtained. The final analysis cohort pooled participants from age 6–32 years-old. 
Table 1 shows the general characteristics of the study population. In adults (21–32 years), mean age 
and body mass index (BMI) were similar across gender. Lower mean diastolic and systolic blood 
pressure (BP) but higher mean pulse rate was obtained from female than male volunteers. In younger 
cohorts, as expected weight, height and BMI increased with age. Diastolic and systolic BP were 
similar across age groups, although pulse rate of 6–10 years and 11–15 year-old cohorts were 
significantly higher than 16–20 years cohort. In the 16–20 year-old cohort, male-to-female ratio was 
1:1. However, there was a preponderance of females in the 6–10 year-old cohort (representing 54% 
against 46%) and in 11–15 year-old cohort (82% vs.18% males).  
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3.2. Hematological Analysis  
The mean, standard deviation, median, minimum/maximum values and 95% reference intervals for 
hematology analytes are given in Table 2. Volunteers had low WBC and platelet counts. Ranges for 
RBC count, hematocrit and hemoglobin values were generally broad when compared to Western 
reference intervals obtained from Pathology Associates Medical Laboratories [22]. The low 
hemoglobin; hematocrit; white blood cell, erythrocyte and platelet counts in Africans compared to 
northern European population or whites have been shown to be related to ethnicity and/or genetic 
factors [23–25]. Significant age differences for red cell indices were obtained when reference intervals 
were partitioned to two broad age groups (6–15 and 16–32 years-old). When computed by the robust 
method as recommended by CLSI C28-A3 guidelines, age differences were evident in the upper values 
for RBC count (p = 0.009), hemoglobin (p < 0.0001) and hematocrit (p < 0.0001) in 16–32 year-old 
compared to 6–15 year-old (Table 3). The increase in hemoglobin, hematocrit and erythrocyte counts; 
as well as the decrease in platelet counts according to age has been reported [4,19,20]. Values were 
within the 2.5 and 97.5 percentiles obtained from Uganda and other African countries with an altitude 
below 2000 m (Table 4). Higher hemoglobin and hematocrit values were reported for Ethiopia 
(at >2300 m above sea level) and lower hemoglobin and hematocrit were noted for Ghana (at 60–150 m 
above sea level). 
3.3. Biochemical Analysis 
The mean, standard deviation, median, minimum/maximum values and 95% reference intervals for 
biochemistry values are summarized in Table 2. Most biochemical analytes were within reference 
intervals reported for the Western population [22,26] with the exception of ALT, γ-GTP, creatinine, 
protein, bilirubin, potassium and sodium. The lower limit for ALT; higher limits for protein, bilirubin 
and sodium have been recorded in the Ugandan population [7]. We also observed significant age 
differences in reference intervals for the following indices: AL-P (p < 0.0001), AST (p < 0.0001), 
amylase (p = 0.02), glucose (p < 0.0001), creatinine (p < 0.0001), urea nitrogen (BUN, p = 0.002), uric 
acid (p < 0.0001), potassium (p = 0.002) and sodium (p < 0.0001) (Table 3). Using the robust method, 
in adults, the reference ranges obtained fell at the lower end of the current reference intervals reported 
for Uganda and other African countries (Table 5). In adolescents and young children there are, at 
present, only a handful of studies available (Table 6). 
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Table 1. Study population characteristics in different age groups (n = 140). 
Analyte 
6–10 Years old (n = 28) 11–15 Years old (n = 28) 16–20 Years old (n = 28) Male >20 Years old (n = 28) Female >20 Years old (n = 28) 
Mean SD Min/Max Mean SD Min/Max Mean SD Min/Max Mean SD Min/Max Mean SD Min/Max 
Age * 8.11 1.52 6/10 12.68 1.25 11/15 17.96 0.99 16/20 22.61 1.26 21/25 22.14 2.14 21/32 
BMI 16.06 1.54 13.9/19.8 18.25 2.38 15.4/24.2 20.60 1.90 18.1/25 21.35 1.82 18/25 22.14 2.56 18.4/28 
Weight 28.35 5.61 17/42 43.18 8.00 33.5/63 57.79 4.27 49/67 62.78 6.36 50.1/75.3 59.74 7.53 48.5/74.5 
Height 132.2 9.99 110.5/153 153.5 7.49 140/169.7 167.8 7.13 157/182.2 171.4 5.90 161.5/184.3 164.2 5.87 153.7/183 
Vital signs                
DBP 69.61 4.49 60/78 71.29 6.92 60/82 73.43 6.55 60/86 73.54 7.10 58/87 72.64 7.37 57/87 
SBP 115.6 8.19 96/126 119.0 8.12 105/129 118.9 8.05 102/131 120.1 13.46 100/142 108.8 11.07 89/135 
Pulse rate 82.82 10.23 66/107 78.79 10.57 60/97 69.64 8.73 55/90 67.25 6.26 55/79 70.25 8.96 55/92 
* Age (year); BMI (kg/m2); weight (kg); height (cm); DBP (diastolic blood pressure; mmHg); SBP (systolic blood pressure, mmHg); pulse rate (bpm). 
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Table 2. Means, median and 95% percentile reference ranges for hematology and biochemistry analytes in 6–32 year old.  
Analyte n Mean SD Median Min/Max 
95% Reference Interval 
Lower Limit 90% CI Upper Limit 90% CI 
WBC § 140 5.66 1.47 5.4 3.3/10.8 3.6 3.3–3.8 9.99 8.3–10.8 
RBC 140 5.06 0.55 4.98 3.9/6.6 4.1 3.9–4.2 6.28 6.11–6.58 
Hb 140 13.75 1.64 13.5 10/18.2 10.55 10–11.6 17.5 16.6–18.2 
Hct 140 41.11 4.35 40.8 31.4/51.5 33.3 31.4–35.5 50.35 49.4–51.5 
Platelet 140 228.5 63.23 222 115/473 118.53 115–135 392.7 337–473 
AL-P 138 151.8 106.9 95.8 42.8/456.2 44.1 42.8–48.2 394.9 355.8–456.2 
ALT 140 15.99 5.61 14.95 6.5/43.5 8.9 6.5–9.7 35.31 24.4–43.5 
AST 139 21.53 4.37 21.3 13.4/36.5 14.3 13.4–15.5 33.9 28.7–36.5 
γ-GTP 139 13.09 6.52 11.6 3.5/45.6 4.05 3.5–5.5 29.85 26–45.6 
Amylase 140 27.21 8.95 25.65 12.7/74.9 15.17 12.7–16.3 52.75 43.4–74.9 
Albumin 140 4.6 0.26 4.61 3.8/5.3 4.08 3.8–4.2 5.04 4.99–5.3 
Protein 140 7.6 0.59 7.5 5.7/9.5 6.25 5.7–6.7 8.6 8.5–9.5 
Bilirubin 140 0.54 0.38 0.4 0.1/1.9 0.1 0.1–0.1 1.7 1.3–1.9 
Cholesterol 140 128.7 25.1 128.1 71.6/188.9 85.55 71.6–91.8 174.15 167.5–188.98 
Glucose 140 84.7 10.23 82.78 67.6/118.96 69.5 67.6–71.8 114.6 103.9–118.96 
Creatinine 140 0.59 0.15 0.6 0.4/1.0 0.4 0.4–0.4 0.95 0.9–1.0 
BUN 140 14.94 4.55 14.16 2.84/29.68 8.29 2.84–9.14 24.9 23.2–29.68 
Uric acid 140 3.85 0.83 3.8 2.1/6.9 2.4 2.1–2.6 5.59 5.3–6.9 
Potassium 140 4.24 0.39 4.24 3.4/5.42 3.57 3.41–3.64 5.27 4.9–5.42 
Sodium 140 139.6 3.2 139.15 135.3/149.4 135.5 135.3–135.8 148.5 145.8–149.4 
§ WBC (leukocyte count, ×109/L); RBC (erythrocyte count, ×1012/L); Hb (hemoglobin, g/dL); Hct (hematocrit, %); Platelet count (×109/L); AL-P (alkaline phosphatase, U/L); ALT (alanine 
aminotransferase, U/L); AST (aspartate aminotransferase, U/L); γ-GTP (γ-glutamyl transpeptidase, U/L); Amylase (serum amylase, U/L); Albumin (g/dL); Protein (total protein, g/dL); 
Bilirubin (total bilirubin, mg/dL); Cholesterol (total cholesterol, mg/dL); Glucose (mg/dL); Creatinine (mg/dL); BUN (urea nitrogen, mg/dL); Uric acid (mg/dL); Potassium (mmol/L); 
Sodium (mmol/L); SD = standard deviation; CI = confidence interval.  
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Table 3. 95% Reference interval for hematology and biochemistry analytes by age group *. 
Analyte 
6–15 Years old 16–32 Years old 
n Lower Limit 90% CI Upper Limit 90% CI n Lower Limit 90% CI Upper Limit 90% CI 
Hematology 
RBC § 56 4.1 3.9–4.2 5.7 5.55–5.84 84 3.9 3.7–4.1 6.4 6.16–6.55 
Hb 56 11.2 10.9–11.5 14.5 14.2–14.8 84 10.9 10.3–11.4 17.9 17.3–18.4 
Hct 55 34.3 33.66–35 42.8 41.9–43.6 84 33.7 32.5–35.2 52.1 50.8–53.3 
Biochemistry 
AL-P 53 111.1 82.8–140.8 419.7 385.1–450.1 78 31.9 26.7–37.47 108.4 100.5–114.5 
AST 55 16.14 14.96–17.5 29.9 28.7–31.1 80 12.99 11.99–14.1 26.11 25–27.15 
Amylase 55 12.42 10.2–15.1 36.3 34.16–38.6 76 14.43 12.6–16.4 37.3 35–39.3 
Glucose 54 66.4 62.7–70.65 109.3 103.9–114 80 67.2 65.4–69.3 91.3 89.1–93.5 
Creatinine 55 0.31 NC 0.61 NC 84 0.43 NC 0.92 NC 
BUN 56 5.14 3.7–6.6 21.29 19.4–22.8 83 6.05 4.69–7.4 24.4 22.5–25.9 
Uric acid 56 2 1.78–2.25 4.88 4.58–5.18 83 2.5 2.28–2.77 5.59 5.34–5.82 
Potassium 52 3.46 3.34–3.57 4.65 4.54–4.74 84 3.58 3.47–3.69 5.02 4.91–5.12 
Sodium 56 134.2 133.5–134.8 141 140.2–141.7 84 133.87 133–134.8 147.4 146.2–148.54 
* Calculated by the robust method recommended by CLSI C28-A3 guideline. NC, not calculated (not possible to calculate) for the subgroup. § RBC (erythrocyte count, ×1012/L);  
Hb (hemoglobin, g/dL); Hct (hematocrit, %); AL-P (alkaline phosphatase, U/L); AST (aspartate aminotransferase, U/L); Amylase (serum amylase, U/L); Glucose (mg/dL); Creatinine 
(mg/dL); BUN (urea nitrogen, mg/dL); Uric acid (mg/dL); Potassium (mmol/L); Sodium (mmol/L). 
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Table 4. Comparison of hematology ranges with other studies in Africa: 16–32 years-old. 
Analyte 
This 
study* 
(16–32 
years old)
Kenya, Uganda, 
Zambia, Rwanda 1
(18–60 years old) 
Uganda 2 
(18–56 
years old) 
Western 
Kenya 3 
(18–34 
years old)
Kericho-
Kenya 4 
(18–55 
years old)
Tanzania 5 
(19–48 
years old) 
Ethiopia 6
(15–45 
years old)
Central 
Africa 7 
(17–58 
years old) 
Togo 8 
(17–58 
years old)
Ghana 9 
(18–59 
years old)
South 
Africa 10 
(18–55 
years old) 
RBC § 3.9–6.4 3.8–6.2 † 3.5–6.1 † 
4.3–6.5 † 
3.4–5.7 
4–6.2 † 4.01–6.12 † 
4.3–5.9 
3.7–5.2 
4.50–6.10 
3.42–5.44 
3.1–6.4 † 3.39–5.83 †
4.19–5.85 † 
3.93–5.40 
n 84 2105 664 160 1541 272 485 150 1349 623 678 
Hb 10.9–17.9 10.5–17.5 † 10.8–17.1 †
11.4–16.9 †
8.0–14.2 
6.7–11.1 † 11.7–17.2 † 
13.9–18.3
12.2–16.6
12.3–17.3 
9.1–14.9 
10–18.4 † 9.8–16.0 †
13.4–17.5 † 
11.6–16.4 
n 84 2105 664 160 1541 276 485 150 1349 624 678 
Hct 33.7–52.1 31.6–51.7 † 31.2–49.5 †
32.6–51.5 †
23.2–44.3
30–50 † 36.5–52.7 † 
41.6–55.1
35.3–48.8
39–52 
28–44 
28–54 † 28.9–48.7 †
39–51 † 
34–48 
n 84 2105 664 160 1541 276 485 150 1349 625 678 
§ RBC (erythrocyte count, ×1012/L); Hb (hemoglobin, g/dL); Hct (hematocrit, %). 1 Karita et al., 2009 [13] and IAVI, 2008 [27]; 2 Eller et al., 2008 [7]; 3 Zeh et al., 2011 [19]; 4 Kibaya et al., 
2008 [6]; 5 Saathoff et al., 2008 [5]; 6 Tsegaye et al., 1999 [9]; 7 Menard et al., 2003 [10]; 8 Kueviakoe et al., 2011 [15]; 9 Dosoo et al., 2012 [16]; 10 Lawrie et al., 2009 [14]. Shown are 95% 
reference intervals. * Calculated by the robust method recommended by CLSI C28-A3 guideline. † Indicates analytes with significant gender differences. If two values are shown, only 
separate male and female reference intervals, respectively were reported. 
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Table 5. Comparison of biochemistry ranges with other studies in Africa: 16–32 years-old. 
Analyte 
This study 
(21–32  
years old) 
Kenya, Uganda, 
Zambia,  
Rwanda 1 
(18–60 years old) 
Uganda 2 
(18–56  
years old)
Western 
Kenya 3 
(18–34  
years old) 
Kericho-
Kenya 4 
(18–55  
years old) 
Tanzania 5 
(19–48  
years old) 
Ghana 6 
(18–59  
years old) 
Enzymes        
AL-P (U/L) § 31.9–108.4 48–164 44–151   45.6–158.4 85–241 † 
n 78 2103 433   236 595 
AST (U/L) 12.99–26.11 14–60 12.3–34.8 † 13.8–50.4 13.8–42.3 † 14.3–48.1 † 14–51 † 
n 80 2103 845 293 1533 269 588 
Amylase 
(U/L) 
14.43–37.3 35–159 45.6–173.6  38.3–163.0 † 42.8–164.4 32–139 † 
n 76 2103 433  1205 270 621 
Metabolism        
Glucose 
(mg/dL) 
67.2–91.3   37.84–118.92 55.8–102.7 52.61–94.23 64.87–115.32
n 80   293 1541 262 622 
Kidney function       
Creatinine 
(mg/dL) 
0.43–0.92 0.53–1.23 0.5–1.2 † 0.57–1.28 0.62–1.15 0.47–1.02 † 0.55–1.33 † 
n 84 2103 851 293 1540 270 615 
BUN (mg/dL) 6.05–24.4  4.6–15.5 † 3.36–14.29 3.92–12.89 † 4.29–13.89 † 2.52–15.97 † 
n 83  848 293 1541 265 622 
Uric acid 
(mg/dL) 
2.5–5.59  3.3–7.8 †   2.76–7.5 † 1.52–6.7 † 
n 83  729   270 620 
Electrolytes        
Potassium 
(mmol/L) 
3.58–5.02  3.4–4.8  3.9–5.8 † 3.83–5.52 † 3.6–5.2 † 
n 84  849  1535 269 583 
Sodium 
(mmol/L) 
133.9–147.4  
135.3–
147.6 † 
 141.4–152.5 133.6–142.5 † 135–150 
n 84  849  1541 257 541 
§ AL-P, alkaline phosphatase; AST, aspartate aminotransferase; BUN, urea nitrogen. 1 Karita, et al., 2009 [13] and IAVI, 2008 [27];  
2 Eller, et al., 2008 [7]; 3 Zeh, et al., 2011 [19]; 4 Kibaya, et al., 2008 [6]; 5 Saathoff, et al., 2008 [5]; 6 Dosoo, et al., 2012 [16]. Shown are 
95% reference intervals. When a value is preceeded by †, analyte was reported to have significant gender differences (p < 0.05).  
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Table 6. Comparison of hematology and biochemistry ranges with other studies in Africa: 
6–15 years-old. 
Analyte This study * 
Uganda 1 
(90% intervals) 
Western Kenya 2 
Hematology    
RBC (×1012/L) § 4.08–5.7 3.8–5.4 † (4.1–5.8) (3.3–5.4) † 
n 56 731 133 
Hb (g/dL) 11.18–14.55 10.0–13.7 † (10.6–15.6) (8.1–14.2) † 
n 56 731 133 
Hct (%) 34.3–42.8 29.2–39.4 † (29.3–48.1) (24.8–43.1) † 
n 55 731 133 
Biochemistry    
AL-P (U/L) § 111.1–419.7   
n 53   
AST (U/L) 16.14–29.9  (17.0–59.2)  (12.0–43.1) † 
n 55  293 
Amylase (U/L) 12.42–36.3   
n 55   
Metabolism    
Glucose (mg/dL) 66.4–109.3  (37.84–118.92) 
n 54  293 
Kidney function    
Creatinine (mg/dL) 0.31–0.61   
n 55   
BUN (mg/dL) 5.14–21.29  (3.36–14.29) 
n 56  293 
Uric acid (mg/dL) 2–4.88   
n 56   
Electrolytes    
Potassium (mmol/L) 3.46–4.65   
n 52   
Sodium (mmol/L) 134.2–141   
n 56   
§ RBC, erythrocyte count; Hb, hemoglobin; Hct, hematocrit; AL-P, alkaline phosphatase; AST, aspartate 
aminotransferase; BUN, urea nitrogen. 1 Except for Lugada et al., 2004 [4], shown are 95% reference intervals. 
When two values are provided, these correspond to male and female ranges, respectively. † Indicates analytes 
with significant age and gender differences (p < 0.05); age range listed is 6–12 years for 1 Lugada et al., 2004 [4]; 
13–17 years for 2 Zeh et al., 2011 [19]. 
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4. Conclusions 
The opportunity to re-assess currently used reference intervals in northern Uganda presented itself 
when we conducted a phase 1b trial in Lira, Uganda. Reference intervals serve as a valuable guide for 
interpretation of laboratory results. Hematology and biochemistry analytes are influenced by a number 
of factors such as sex, age, ethnic origin, environment (including geographical location, access to 
health care), constitutional abnormalities (thalassemia, sickle cell disease), pathologic conditions 
(malaria, HIV and HBV viral infections); and to some extent demographic changes and technological 
advancement in analyte measurements [4–7,13–20,23,27,28].  
The revised international guidelines from CLSI recommend that if it is not possible to establish 
detailed reference studies from at least 120 individuals, validation using as few as 20 samples could be 
helpful together with comparison using published reference intervals and performing posteriori 
methods [29,30]. We, thus, examined and compared the variability of hematological and biochemical 
analytes obtained during participant screening for trial enrollment. The analytes were commonly used 
for clinical assessments to guide inclusion/exclusion into the trial and for adverse event evaluation.  
The studied population is heterogeneous with regards to age and gender. However, overall, the 
upper and lower limits of the reference intervals obtained in this study were almost the same as the 
limits reported in previous adult hematologic reference intervals (Table 4). Trends of age-specific 
differences in some parameters were also evident although this needs further verification in larger 
cohorts (Table 6). At present there are few reports available for adolescents and younger age groups, 
especially on biochemistry analytes in Africa [11,19,31,32]. 
Whether gender or age would alter the reference intervals obtained in the present study is for further 
studies. The screening activity did not screen out all medical conditions such as hepatitis B, HIV or 
other parasitic infections except for malaria. We have no information on social habits (tobacco use, 
diet, alcohol consumption, exercise, etc.) as these were not obtained during enrollment of the 
volunteers (e.g., factors such as smoking has been reported to affect hemoglobin values [14]). We did, 
however, have a well-defined trial inclusion and exclusion criteria, and all subject were evaluated for 
both hematological and biochemical indices. Volunteers were encouraged to come for screening to the 
study clinic after fasting for at least 8 h. Breakfast was given to all participants afterwards and this 
assisted in a high level of compliance with this request, although in some cases fasting was interpreted 
as an instruction not to eat or drink and, thus, some volunteers were mildly dehydrated during blood 
sample collection. Nevertheless, the study provides preliminary data needed to facilitate health care 
and research trials in a population in which reference interval generation has not yet been done. 
Participants in the study also represent volunteers that would participate in clinical trials. Importantly, 
we also highlight the need for local data especially in younger age groups as their participation in 
clinical trial is solicited. 
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